Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs
Patients which are treated with stimulants (e.g., CNS stimulants, sympathomimetic amine, or anorectic/anorexigenic), such as patients being treated for attention deficit/hyperactivity disorder or obesity, often are at risk in developing high blood pressure. Similarly, patients which are treated with analgesics such as non-steroidal anti-inflammatory drugs (NSAIDs) over an extended period of time risk developing high blood pressure. These and other iatrogenic therapies (therapies which inadvertently cause an increase in, e.g., blood pressure) are addressed by providing the patient with one or more antihypertensive drugs, most preferably calcium channel blockers, during the treatment period. The CNS or NSAIDs can be provided separately or together with the antihypertensive drugs or as part of a combined composition. The adjunctive therapy can prevent or reduces cardiovascular disease and other complications of high blood pressure attendant with these iatrogenic therapies.
1. An oral dosage composition comprising:
amlodipine or a pharmaceutically acceptable salt thereof; and
celecoxib or a pharmaceutically acceptable salt thereof,
wherein said amlodipine and celecoxib or pharmaceutically acceptable salts thereof are present together in a single dosage form.
2. The oral dosage composition of claim 1 wherein said single dosage form is selected from the group consisting of a tablet, dragee, liquid, drop, capsule, caplet and gelcap.
3. The oral dosage composition of claim 1 , wherein said amlodipine or pharmaceutically acceptable salt thereof is present in the single dosage form at a dose of about 10.1 mg to about 15 mg.
4. The oral dosage composition of claim 1 , further comprising a pharmaceutically acceptable excipient.
5. The oral dosage composition of claim 4 , wherein said pharmaceutically acceptable excipient comprises one or more of lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure buffers, coloring, flavoring or aromatic substances.
6. The oral dosage form of claim 4 , wherein said pharmaceutically acceptable excipient comprises one or more of an inert diluent, granulating and disintegrating agents, binding agents, and lubricating agents.
7. The oral dosage composition of claim 6 , wherein said inert diluent comprises lactose.
8. The oral dosage composition of claim 6 , wherein said granulating and disintegrating agent comprises cornstarch.
9. The oral dosage composition of claim 6 , wherein said binding agent comprises starch.
10. The oral dosage composition of claim 6 , wherein said lubricating agent comprises magnesium stearate.
11. The oral dosage composition of claim 4 , wherein said pharmaceutically acceptable excipient comprises one or more of water, salt solutions, alcohols, gum arabic, vegetable oils, benzyl alcohols, polyethylene glycols, gelate, carbohydrates, starch, magnesium stearate, talc, silicic acid, viscous paraffin, perfume oil, fatty acid monoglyceride, fatty acid diglyceride, pentaerythritol fatty acid ester, hydroxymethylcellulose, and polyvinylpyrrolidone.